These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 22171556)

  • 1. A modified thrombin clotting time test as a quality control marker for heparin contamination in obstetric intraoperative cell salvage.
    Sullivan IJ; Hicks MK; Faulds JN; Carson PJ; Noble RS
    Transfus Med; 2012 Feb; 22(1):68-70. PubMed ID: 22171556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of S-hexyl-L-cysteine derivatives on prothrombin activation and clotting time determined in the presence of heparin.
    Midura-Nowaczek K; Bruzgo I; Krajewska D
    Adv Med Sci; 2009; 54(1):47-50. PubMed ID: 19648086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J
    J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation protein function: the influence of acetaldehyde-modified heparin on thrombin activity.
    Brecher AS; Fu Q
    J Investig Med; 1999 Jan; 47(1):76-80. PubMed ID: 10071484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
    Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
    Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality assessment of intraoperative blood salvage and autotransfusion.
    Spain DA; Miller FB; Bergamini TM; Montgomery RC; Richardson JD
    Am Surg; 1997 Dec; 63(12):1059-63; discussion 1063-4. PubMed ID: 9393253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses.
    Monreal L; Villatoro AJ; Monreal M; Espada Y; Anglés AM; Ruiz-Gopegui R
    Am J Vet Res; 1995 Oct; 56(10):1281-5. PubMed ID: 8928943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of thrombin generation in whole blood--the effect of heparin and aspirin.
    Kessels H; Béguin S; Andree H; Hemker HC
    Thromb Haemost; 1994 Jul; 72(1):78-83. PubMed ID: 7974380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass.
    Huyzen RJ; van Oeveren W; Wei F; Stellingwerf P; Boonstra PW; Gu YJ
    Ann Thorac Surg; 1996 Aug; 62(2):533-7. PubMed ID: 8694618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactate dehydrogenase and Haemolysis Index as quality control markers of haemolysis in intra-operative cell salvage.
    Sullivan IJ; Faulds JN
    Transfus Med; 2013 Oct; 23(5):326-9. PubMed ID: 23849190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin clotting time.
    Ignjatovic V
    Methods Mol Biol; 2013; 992():131-8. PubMed ID: 23546710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR
    Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anticoagulant capacity of plasmatic unfractionated heparin decreases at 23 degrees C.
    Stief TW
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):209-12. PubMed ID: 17287642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standardization of coagulation tests.
    Opartkiattikul N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a new potent heparin. 7th communication: A comparative study of a new potent heparin in human after i.v. application.
    Bhargava AS; Wendt H; Günzel P
    Arzneimittelforschung; 1981; 31(2):386-8. PubMed ID: 7194658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
    Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
    Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective anticoagulation with active site blocked factor IXa in synthetic patch vascular repair results in decreased blood loss and operative time.
    Spanier TB; Oz MC; Madigan JD; Rose EA; Stern DM; Nowygrod R; Schmidt AM
    ASAIO J; 1997; 43(5):M526-30. PubMed ID: 9360098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.